Related Experiment Video
Updated: Jun 18, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Baseline stool toxin concentration is associated with risk of recurrence in children with Clostridioides difficile
Thomas J Sandora1,2, Larry K Kociolek3,4, David N Williams5
1Division of Infectious Diseases, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, United States.
Insights
Higher stool toxin levels in children with Clostridioides difficile infection (CDI) predict recurrence. Toxin quantification may aid in assessing CDI severity and predicting outcomes in pediatric patients.
Area of Science:
- Pediatric Infectious Diseases
- Gastroenterology
- Microbiology
Background:
- Clostridioides difficile infection (CDI) poses significant risks in adults, with toxin levels linked to disease severity and recurrence.
- Evaluating toxin concentration as a predictive marker in pediatric CDI is crucial for understanding disease progression.
Purpose of the Study:
- To investigate the association between baseline stool toxin A and B concentrations and severe outcomes or recurrence in children with CDI.
- To assess the predictive value of toxin levels for CDI severity and clinical outcomes in pediatric patients.
Main Methods:
- A prospective cohort study involving 187 pediatric inpatients (aged 2-17 years) diagnosed with CDI.
- Measurement of baseline stool toxin A and B concentrations using ultrasensitive single-molecule array assay.
- Follow-up for 40 days to assess severe outcomes and recurrence, with plasma cytokine analysis in available samples.
Main Results:
- No significant difference in toxin levels between severe and non-severe baseline disease, or between severe outcomes and no severe outcomes.
- A significant association was found between higher baseline stool toxin A+B concentration and CDI recurrence (P = .024).
- Elevated plasma granulocyte colony-stimulating factor was observed in CDI patients compared to controls (P < .001).
Conclusions:
- Higher baseline stool toxin concentrations are a significant predictor of CDI recurrence in children.
- Toxin quantification warrants inclusion in pediatric CDI treatment trials for severity assessment and outcome prediction.
Background:
In adults with Clostridioides difficile infection (CDI), higher stool concentrations of toxins A and B are associated with severe baseline disease, CDI-attributable severe outcomes, and recurrence. We evaluated whether toxin concentration predicts these presentations in children with CDI.
Methods:
We conducted a prospective cohort study of inpatients aged 2-17 years with CDI who received treatment. Patients were followed for 40 days after diagnosis for severe outcomes (intensive care unit admission, colectomy, or death, categorized as CDI primarily attributable, CDI contributed, or CDI not contributing) and recurrence. Baseline stool toxin A and B concentrations were measured using ultrasensitive single-molecule array assay, and 12 plasma cytokines were measured when blood was available.
Results:
We enrolled 187 pediatric patients (median age, 9.6 years). Patients with severe baseline disease by IDSA-SHEA criteria (n = 34) had nonsignificantly higher median stool toxin A+B concentration than those without severe disease (n = 122; 3,217.2 vs 473.3 pg/mL; P = .08). Median toxin A+B concentration was nonsignificantly higher in children with a primarily attributed severe outcome (n = 4) versus no severe outcome (n = 148; 19,472.6 vs 429.1 pg/mL; P = .301). Recurrence occurred in 17 (9.4%) of 180 patients. Baseline toxin A+B concentration was significantly higher in patients with versus without recurrence: 4,398.8 versus 280.8 pg/mL (P = .024). Plasma granulocyte colony-stimulating factor concentration was significantly higher in CDI patients versus non-CDI diarrhea controls: 165.5 versus 28.5 pg/mL (P < .001).
Conclusions:
Higher baseline stool toxin concentrations are present in children with CDI recurrence. Toxin quantification should be included in CDI treatment trials to evaluate its use in severity assessment and outcome prediction.
More Related Videos
06:51Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
Related Concept Videos
Serum Laboratory Studies, Stool Test, Breath Test
Bacterial Toxins
Bacterial Gastroenteritis